Physician profile
Gregory Ross Bernstein
NPI 1598056673
$3,590.04
in general payments reported to CMS, 2019-2025
23 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $280 · 2021: $90.88 · 2022: $565 · 2023: $1,000 · 2024: $973 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.41 |
| Education | $131.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $689.78 | 2021-2025 | Rinvoq, Skyrizi, Viberzi |
| Pfizer INC. | $557.50 | 2022-2025 | |
| Celgene Corporation | $472.33 | 2021-2024 | Zeposia |
| Stryker Corporation | $280.00 | 2020 | |
| Aimmune Therapeutics, INC. | $199.79 | 2024-2025 | Vowst, Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.97 | 2022-2024 | Xifaxan, Plenvu, Trulance |
| Phathom Pharmaceuticals, INC. | $172.97 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $162.77 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $118.97 | 2023 | Zeposia |
| Celltrion USA INC. | $100.70 | 2023-2024 | Zymfentra, Yuflyma |
| Ferring Pharmaceuticals INC. | $89.93 | 2021-2024 | Rebyota |
| Genzyme Corporation | $84.72 | 2024-2025 | |
| Boston Scientific Corporation | $78.41 | 2025 | Cre Pro, Compliance Endokit |
| Lilly USA, LLC | $73.73 | 2023-2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $53.49 | 2022-2023 | Entyvio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45.65 | 2023-2025 | Dupixent |
| Capsovision, INC. | $45.62 | 2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $45.45 | 2023-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $34.72 | 2022-2025 | |
| Ardelyx, INC. | $32.49 | 2023 | Ibsrela |
| Braintree Laboratories, INC. | $32.01 | 2022 | |
| Nestle Healthcare Nutrition INC. | $24.36 | 2023 | |
| Echosens North America, INC. | $18.68 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.